Inhibitory effect of misoprostol on gastric acid secretion in vitro. Qualitative differences from natural prostaglandins.
The synthetic PGE1 analog, misoprostol, was shown to have a marked inhibitory effect on gastric secretion as determined in the isolated gastric fundus from immature rats. It inhibited both the unstimulated and pentagastrin-stimulated acid secretion at 10(-7)-10(-4) molar concentrations. Its effect was different from that of PGE1 and PGE2, which did not affect basal acid secretion (up to 3 x 10(-5) M), although they inhibited to the same extent as misoprostol the pentagastrin-induced acid secretion. When given by "mucosal" application, misoprostol (10(-7)-10(-5) M) behaved similar to the mast cell stabilizer, compound FPL 52694, but its maximum reduction response was only 50%. The above data suggest that misoprostol has additional antisecretory mechanisms of action not shared by the classical natural prostaglandins.
D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology*; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002867:Chromones / Q000494:pharmacology; D015232:Dinoprostone / Q000494:pharmacology*; D005744:Gastric Acid / Q000187:drug effects / Q000378:metabolism*; D005748:Gastric Fundus; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D016595:Misoprostol; D010418:Pentagastrin / Q000037:antagonists & inhibitors; D051381:Rats
D000897:Anti-Ulcer Agents; D002867:Chromones; D016595:Misoprostol; C029061:FPL-52694; D010418:Pentagastrin; D000527:Alprostadil; D015232:Dinoprostone